By the way, is there a reason for the continuing run-up?
I seem to be getting labeled as a fanboy because of, well, it's not worth talking about.
Partly to offset that--is anything unexpected happening? I could see a small move because there's a chance that the costly gene patents litigation may end. But 12+%?! (If I replaced the '?' with '@' would that collection of symbols be cursing?) Didn't notice any dramatic developments in 'other' tests, nothing new on companion diagnostics at all and predictions of business changes in the future, which might be positive, but definitely carry risk.
in today's HFT market who knows why for certain. Seems like with HFTs controlling 70%+ of the market activity they don't care re fundamentals...just the price action. Until the bubble pops or poops take your pick.
Not saying this is a bubble here but then I'm not a HFT so I wouldn't recognize one.
Doesn't seem to capture the action. ET DOES phone home now and then, especially since the flash crash. Somebody [thinks he] has an idea.
I'm particularly concerned that this may be a reaction to the perceived end of gene patent litigation expense. That fight has been going on for what, 30 years? and it isn't likely to end with this case. And there's nothing like a "genius" who has been proved wrong to knock a stock down.
Or maybe someone expecting a spigot to open from Europe on BRACnalysis, or the US on Prolaris? I don't believe in sudden floods of business, myself. Most of the time you need to do a tough selling job. Sometimes big pharma makes it look easier than that because they can quickly piggyback a new product on their [huge] ongoing sales effort. A slow business ramp probably wouldn't annoy buyers as much as a new legal theory for opposing gene patents, but it wouldn't do the stock price any good, either.
Anyone know if maybe Cramer or IBD or something comparable have been touting MYGN?